Philip Siberg
Chief Executive Officer
Q3 report presentation
Philip Siberg, CEO of Senzime, will present the 2025 Q3 report on Oct 29.
Q2 2025 report presentation
When the Q3 report presentation is available, you will see it at this page.
Safeguarding patients during anesthesia and recovery
Senzime develops CE and FDA-cleared precision-based patient monitoring solutions. Our products are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime is listed on Nasdaq Main Market (SEZI) and cross traded in the US on the OTCQX list (SNZZF).
Press release
Invitation to presentations of Senzime’s third quarter 2025 report
Press release
Senzime launches EMGINE, the next-generation software suite advancing neuromuscular monitoring
Press release
Senzime welcomes new European pediatric guidelines recommending EMG-based neuromuscular monitoring
Financial info April - June 2025
FIRST SIX MONTHS OF 2025: SALES INCREASED BY 90% IN LOCAL CURRENCIES
We have strong momentum. Net sales increased by 82% to SEK 49.2 million (27.0), corresponding to 90% growth in local currencies. The increase was driven by sales of next-generation TetraGraph monitors and TetraSens disposable sensors.
49,2
Net sales, TSEK
82
Net sales, % increase
64
Sales of disposable sensors, % increase
63.8
Gross margin excluding depreciation, %
Subscribe
Subscribe to our financial news to receive updates on our latest financial performance, strategic initiatives, and upcoming opportunities.